This version of the registration was submitted prior to the Lobbying Transparency Act coming into force on May 4, 2020. Due to different information requirements at that time, the registration is presented in the following format.
Registration ID: 891881 Submitted by lobbyist on: December 16, 2018 06:29:29 PM Accepted by Registrar on: December 17, 2018 09:35:58 AM
Designated Filer Information
Keon, James J
4120 Yonge Street Suite 409
Toronto, ON, M2P 2B8
416-223-2333
Canada
Organization Information
Canadian Generic Pharmaceutical Association (CGPA)
The CGPA's mission is to promote an environment which supports and enhances the provision of affordable generic medications to Canadians and patients around the world. The Association researches and develops positions regarding a wide variety of policies, regulations and legislation that affects our member companies. We promote our sector's interests by publishing material as well as directly contacting government officials, the media and other opinion leaders and decision makers.
4120 Yonge Street Suite 409
Toronto, BC, M2P 2B8
416-223-2333
Canada
Relevant Affiliates
The client has no relevant affiliates.
Government or Government Agency Funding
The organization does not receive any funding from a government or government agency.
Other Controlling or Directing Interests
The organization has no other controlling or directing interests.
Active Registration Period
December 16, 2018
June 16, 2019
Organization's In-House Lobbyists
Name:
Connell, Jeff
December 16, 2018
Inactivation Date:
June 27, 2019
BC Public Office Background
This individual has not held any public office positions in BC.
Lobbying Activities
Health
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Introduction, modification or repeal of legislation, a bill or regulation
Developing a regulatory pathway for biosimilars. Addressing use of brand coupon cards. Protecting the interests of Canada's generic pharmaceutical industry during implementation of the Comprehensive Economic and Trade Agreement and the USMCA. Implementation of commitments made by British Columbia pursuant to its involvement with the pan-Canadian Pharmaceutical Alliance. Use of Ontario reference price. Amendment of the Drug Price Regulation in respect of the Maximum Allowable List Price to bring it in line with pCPA tiered pricing model and elimination of exclusive listings. Payment of distribution fees by the government. Promoting greater utilization of generic prescription medicines. Price increase policy. Scope of listings. National Pharmacare initiative.
Target Contacts
Target Type
Name
Title or Constituency
Date Added
Minister
Dix,
Adrian
Minister of Health
December 16, 2018
Public Agency
Health
December 16, 2018
Name:
Cox, Jody
December 16, 2018
Inactivation Date:
June 27, 2019
BC Public Office Background
This individual has not held any public office positions in BC.
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Developing a regulatory pathway for biosimilars. Protecting the interests of Canada's generic pharmaceutical industry during implementation of the Comprehensive Economic and Trade Agreement and the USMCA.
Target Contacts
Target Type
Name
Title or Constituency
Date Added
Public Agency
Health
December 16, 2018
Public Agency
Minister of State for Trade
December 16, 2018
Name:
Keon, James
December 16, 2018
Inactivation Date:
June 27, 2019
BC Public Office Background
This individual has not held any public office positions in BC.
Lobbying Activities
Health
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Introduction, modification or repeal of legislation, a bill or regulation
Developing a regulatory pathway for biosimilars. Addressing use of brand coupon cards. Protecting the interests of Canada's generic pharmaceutical industry during implementation of the Comprehensive Economic and Trade Agreement and the USMCA. Implementation of commitments made by British Columbia pursuant to its involvement with the pan-Canadian Pharmaceutical Alliance. Use of Ontario reference price. Amendment of the Drug Price Regulation in respect of the Maximum Allowable List Price to bring it in line with pCPA tiered pricing model and elimination of exclusive listings. Payment of distribution fees by the government. Promoting greater utilization of generic prescription medicines. Price increase policy. Scope of listings. National Pharmacare initiative.
